(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide | |
---|---|
Trade Name | |
Orphan Indication | Chronic myeloid leukemia |
USA Market Approval | USA |
USA Designation Date | 2011-03-18 00:00:00 |
Sponsor | NATCO Pharma Limited;Natco House;Hyderbad 500033 |
Related Access Program
Pusan National University Hospital – Chronic Myeloid Leukemia
University of California, San Francisco – Chronic Myeloid Leukemia
Emory University – Chronic Myeloid Leukemia
Pusan National University Hospital – Chronic myeloid leukemia
University of California, San Francisco – Chronic myeloid leukemia
Pfizer – Chronic myeloid leukemia
Emory University – Chronic myeloid leukemia